Press Releases

SAN DIEGO, Sept. 3, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable infor

BOSTON, Sept. 3, 2019 /PRNewswire/ -- The Society for Participatory Medicine (SPM), the preeminent organization in promoting true partnersh

PHOENIX, Sept. 3, 2019 /PRNewswire/ -- With every birthday comes a wish and EōS Fitness is marking its five-year birthday milestone with a wish to raise money for the Children's Cancer Res

DALLAS, Sept. 3, 2019 /PRNewswire/ -- SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced today that the Company has submitted its formal application to list its common shares on the NASDAQ Capital Market. Concurrently, SWK announced the appointment of Winston Black

Safety Outcomes of Interest Observed in Less Than 1% Cases; Zero Deaths ReportedGreater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 MinutesNASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 3, 2019 /PRNewswire/ - Correvio Pharma Corp. (NAS

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it has commenced an underwritten initial public offering of up to 5,000,000 shares of its common stock. All

FOSTER CITY, Calif., Sept. 3, 2019 /PRNewswire/ -- SutroVax, Inc., a biopharmaceutical company dedicated to the development of best-in-class conjugate vaccines and novel complex antigen-based vacci

FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive results from AMPLIFY, a pivotal Phase 3 study of tenapanor in combination with phosphate binders in patients with chroni

VALENCIA, Calif., Sept. 3, 2019 /PRNewswire/ -- Bioness, Inc., the leading provider of advanced, clinically supported medical devices for the treatment of chronic pain of peripheral nerve origin, is attending the 49th International Continence Society (ICS) Annual Meeting in Gothenburg, Sweden from 3-6 Septembe

EUGENE, Ore., Sept. 3, 2019 /PRNewswire/ -- The Health & Safety Institute (HSI) today announces the closing of its acquisition by Waud Capital Partners from the Riverside Company. Chief Executive Officer Chad Birckelbaw and the current management team will continue to lead HSI.